Teva
NYSE:TEVAPharmaPetah Tikva, Israel, Israel · Est. 1901 · 43,000 employees
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
4
Indications↗
Distinct diseases across all programs
437
Clinical Trials↗
All sponsored trials (all statuses)
86
Orange Book Patents
Across 6 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 22
Phase 12
By Therapeutic Area
top 4
Gastroenterology
125%
Neurology
125%
Dermatology
125%
Oncology
125%
R&D Momentum
48/100
Pipeline Velocity
11/100
Trial Completion Rate
88/100
Pipeline Concentration
25/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 4, 2026
Active, not recruiting
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
Oct 30, 2026
Recruiting
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
Earlier
Oct 15, 2026TrialA Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
Oct 10, 2026TrialAn Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Oct 10, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Oct 7, 2026TrialA Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
Oct 7, 2026TrialA 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination Compared to Fluticasone Propionate, Albuterol Sulfate or Placebo Delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older With Asthma
Oct 2, 2026TrialA Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
3 more events
Oct 1, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY® (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy
Sep 9, 2026TrialA Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Escalating Dose Trial in Healthy Participants to Assess Pharmacokinetics, Safety, and Tolerability of TEV-56286 at Clinical and Supratherapeutic Doses
Aug 28, 2026TrialReal-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$15.6B
Revenue
—
Cash
CEOKåre Schultz
Founded1901
Employees43,000
HQPetah Tikva, Israel, Israel
ExchangeNYSE:TEVA
Websitetevapharm.com
LinkedInCompany Page
Therapeutic Focus
NeurologyPsychiatryOncologyCardiovascularMetabolic & EndocrineImmunologyOphthalmologyOtherRespiratoryDermatologyInfectious DiseaseNephrologyGastroenterologyHematologyMusculoskeletal
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology
Neurology
Regulatory
Regulatory Timeline
20258 events
FDAAug 5
Ajovy — AJOVY
Application BLA761089
FDAJun 27
CellCept — CELLCEPT
Application NDA050722
FDAJun 27
CellCept — CELLCEPT
Application NDA050758
FDAJun 27
CellCept — CELLCEPT
Application NDA050723
FDAJun 27
CellCept — CELLCEPT
Application NDA050759
FDAMay 1
Depakote — DEPAKOTE ER
Application NDA021168
FDAMay 1
Depakote — DEPAKOTE
Application NDA018723
FDAMay 1
Depakote — DEPAKOTE
Application NDA019680
202612 events
FDAJul 29
CellCept — CELLCEPT
Application NDA050723
FDAJul 29
CellCept — CELLCEPT
Application NDA050723
FDAJul 29
CellCept — CELLCEPT
Application NDA050758
FDAJul 29
CellCept — CELLCEPT
Application NDA050759
FDAJul 29
CellCept — CELLCEPT
Application NDA050759
FDAJul 29
CellCept — CELLCEPT
Application NDA050722
FDAJul 29
CellCept — CELLCEPT
Application NDA050758
FDAJul 29
CellCept — CELLCEPT
Application NDA050722
FDAJun 5
Ajovy — AJOVY
Application BLA761089
FDAMar 31
Depakote — DEPAKOTE
Application NDA018723
FDAMar 31
Depakote — DEPAKOTE ER
Application NDA021168
FDAMar 31
Depakote — DEPAKOTE
Application NDA019680
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)